IL248249A0 - 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline prodrug - Google Patents
1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline prodrugInfo
- Publication number
- IL248249A0 IL248249A0 IL248249A IL24824916A IL248249A0 IL 248249 A0 IL248249 A0 IL 248249A0 IL 248249 A IL248249 A IL 248249A IL 24824916 A IL24824916 A IL 24824916A IL 248249 A0 IL248249 A0 IL 248249A0
- Authority
- IL
- Israel
- Prior art keywords
- hexanediyl
- dioxo
- prodrug
- proline
- bis
- Prior art date
Links
- HZLAWYIBLZNRFZ-VXGBXAGGSA-N cphpc Chemical compound OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(O)=O)CCC1 HZLAWYIBLZNRFZ-VXGBXAGGSA-N 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1407506.3A GB201407506D0 (en) | 2014-04-29 | 2014-04-29 | Novel compound |
| PCT/EP2015/058998 WO2015165833A1 (en) | 2014-04-29 | 2015-04-27 | A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL248249A0 true IL248249A0 (en) | 2016-11-30 |
Family
ID=50972033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL248249A IL248249A0 (en) | 2014-04-29 | 2016-10-09 | 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline prodrug |
| IL279120A IL279120A (en) | 2014-04-29 | 2020-12-01 | 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-D-proline prodrug |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL279120A IL279120A (en) | 2014-04-29 | 2020-12-01 | 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-D-proline prodrug |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9701668B2 (enExample) |
| EP (1) | EP3137457B1 (enExample) |
| JP (1) | JP6445046B2 (enExample) |
| KR (1) | KR20160145617A (enExample) |
| CN (1) | CN106459016B (enExample) |
| AR (1) | AR100204A1 (enExample) |
| AU (1) | AU2015252184B2 (enExample) |
| BR (1) | BR112016025129A2 (enExample) |
| CA (1) | CA2947060C (enExample) |
| CL (1) | CL2016002721A1 (enExample) |
| CR (1) | CR20160508A (enExample) |
| DO (1) | DOP2016000292A (enExample) |
| EA (1) | EA032129B1 (enExample) |
| ES (1) | ES2731253T3 (enExample) |
| GB (1) | GB201407506D0 (enExample) |
| IL (2) | IL248249A0 (enExample) |
| MA (1) | MA39406B1 (enExample) |
| MX (1) | MX2016014246A (enExample) |
| MY (1) | MY191088A (enExample) |
| PE (1) | PE20161558A1 (enExample) |
| PH (1) | PH12016502006B1 (enExample) |
| SG (1) | SG11201608371RA (enExample) |
| TW (1) | TWI676624B (enExample) |
| UA (1) | UA119871C2 (enExample) |
| UY (1) | UY36098A (enExample) |
| WO (1) | WO2015165833A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
| GB201518950D0 (en) * | 2015-10-27 | 2015-12-09 | Glaxosmithkline Ip Dev Ltd | Compound |
| GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69808017T2 (de) | 1997-10-31 | 2003-04-30 | F. Hoffmann-La Roche Ag, Basel | D-Prolinderivate |
| US6903129B2 (en) * | 2001-12-14 | 2005-06-07 | Hoffman-La Roche Inc. | D-proline prodrugs |
| EP1636240A1 (en) | 2003-06-05 | 2006-03-22 | Pfizer Products Inc. | Beta-lactamase inhibitor prodrug |
| GB0313386D0 (en) | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
| AU2006234532A1 (en) | 2005-04-12 | 2006-10-19 | Meiji Seika Kaisha, Ltd. | 2-Thioethenyl carbapenem derivative |
| GB0712503D0 (en) | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
| UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
-
2014
- 2014-04-29 GB GBGB1407506.3A patent/GB201407506D0/en not_active Ceased
-
2015
- 2015-04-27 UY UY0001036098A patent/UY36098A/es not_active Application Discontinuation
- 2015-04-27 WO PCT/EP2015/058998 patent/WO2015165833A1/en not_active Ceased
- 2015-04-27 US US14/787,608 patent/US9701668B2/en not_active Expired - Fee Related
- 2015-04-27 EP EP15720312.6A patent/EP3137457B1/en active Active
- 2015-04-27 AR ARP150101262A patent/AR100204A1/es active IP Right Grant
- 2015-04-27 AU AU2015252184A patent/AU2015252184B2/en not_active Ceased
- 2015-04-27 CR CR20160508A patent/CR20160508A/es unknown
- 2015-04-27 MX MX2016014246A patent/MX2016014246A/es active IP Right Grant
- 2015-04-27 EA EA201692185A patent/EA032129B1/ru not_active IP Right Cessation
- 2015-04-27 PE PE2016001934A patent/PE20161558A1/es unknown
- 2015-04-27 BR BR112016025129A patent/BR112016025129A2/pt not_active Application Discontinuation
- 2015-04-27 KR KR1020167029703A patent/KR20160145617A/ko not_active Ceased
- 2015-04-27 CN CN201580023347.0A patent/CN106459016B/zh not_active Expired - Fee Related
- 2015-04-27 TW TW104113338A patent/TWI676624B/zh not_active IP Right Cessation
- 2015-04-27 MY MYPI2016703952A patent/MY191088A/en unknown
- 2015-04-27 MA MA39406A patent/MA39406B1/fr unknown
- 2015-04-27 SG SG11201608371RA patent/SG11201608371RA/en unknown
- 2015-04-27 CA CA2947060A patent/CA2947060C/en active Active
- 2015-04-27 UA UAA201612105A patent/UA119871C2/uk unknown
- 2015-04-27 JP JP2016565212A patent/JP6445046B2/ja not_active Expired - Fee Related
- 2015-04-27 ES ES15720312T patent/ES2731253T3/es active Active
-
2016
- 2016-10-09 IL IL248249A patent/IL248249A0/en active IP Right Grant
- 2016-10-10 PH PH12016502006A patent/PH12016502006B1/en unknown
- 2016-10-26 CL CL2016002721A patent/CL2016002721A1/es unknown
- 2016-10-28 DO DO2016000292A patent/DOP2016000292A/es unknown
-
2017
- 2017-06-01 US US15/610,984 patent/US9873686B2/en active Active
- 2017-12-11 US US15/837,297 patent/US10597385B2/en active Active
-
2020
- 2020-12-01 IL IL279120A patent/IL279120A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2025038I1 (no) | Risdiplam or a pharmaceutically acceptable salt thereof - forlenget | |
| NO2022058I1 (no) | Capmatinib or a pharmaceutically acceptable salt thereof | |
| NO2024009I1 (no) | Gefapixant, or a pharmaceutically acceptable salt thereof | |
| ZA201605622B (en) | 1,3-benzodioxole derivative | |
| MA42036A (fr) | Analogues nucléosidiques 5'-substitués | |
| FIC20253004I1 (fi) | Seladelpaari tai sen farmaseuttisesti hyväksyttävä suola, erityisesti seladelpaari-L-lysiinidihydraatti | |
| IL251976A0 (en) | Phage therapy | |
| GB201620546D0 (en) | A distributed ledger | |
| GB201614571D0 (en) | Speckle reduction | |
| IL279120A (en) | 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-D-proline prodrug | |
| SG11201608986WA (en) | A locking gimbal | |
| EP3164136A4 (en) | Prodrug compounds and uses therof | |
| SG11201803584RA (en) | 1,4-dicarbonyl-piperidyl derivatives | |
| IL258217A (en) | 2,3,4,5 tetrahydropyridin-6-amine derivatives | |
| GB201612872D0 (en) | Prodrug compounds | |
| GB201521215D0 (en) | Prodrug | |
| GB2531817B (en) | Accelerometer | |
| SI3155169T1 (sl) | CF papir | |
| IL267264A (en) | Auxiliary substances | |
| IL249519B (en) | History of abscisic acid - converted at the 3' position | |
| GB201618479D0 (en) | Adjuvants | |
| HK1232886A1 (en) | A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline | |
| GB201621375D0 (en) | Adjuvants | |
| EP3210974A4 (en) | Prodrug | |
| HK1263345A1 (en) | Mmp-sensitive taxane prodrug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |